Aquestive Therapeutics' stock has declined significantly in the past five years due to shrinking revenue. Shareholders hope for strong revenue growth to offset lack of profits. Recent improvement in total shareholder return could indicate a positive turnaround, but investors should consider various factors and risks before making decisions.